newsfilter
← Latest News
Business Wire·

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a differentiated, potential